Janux is a new Buy at Truist ahead of catalyst rich H2
Source: SeekingAlpha
2025-09-10 14:43:42 ET
More on Janux Therapeutics
- Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash
- Piper Sandler initiates coverage of oncology companies
- Seeking Alpha’s Quant Rating on Janux Therapeutics
- Historical earnings data for Janux Therapeutics
- Financial information for Janux Therapeutics
Read the full article on Seeking Alpha
For further details see:
Janux is a new Buy at Truist ahead of catalyst rich H2
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
-3.62% G/L:
$14.11 Last:
164,253 Volume:
$14.50 Open:
JANX Latest News
May 07, 2026 04:01:00 pm
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
April 27, 2026 04:01:00 pm
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 16, 2026 04:01:00 pm
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
